Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
United Parcel Service
UPS
|
$445M |
| 2 |
DexCom
DXCM
|
$427M |
| 3 |
WIX.com
WIX
|
$371M |
| 4 |
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
|
$270M |
| 5 |
Advanced Micro Devices
AMD
|
$265M |
Top Sells
| 1 |
Apple
AAPL
|
$1.21B |
| 2 |
Merck
MRK
|
$535M |
| 3 |
Microchip Technology
MCHP
|
$526M |
| 4 |
Illumina
ILMN
|
$473M |
| 5 |
Bristol-Myers Squibb
BMY
|
$455M |
Sector Composition
| 1 | Technology | 30.59% |
| 2 | Healthcare | 18.35% |
| 3 | Consumer Discretionary | 11.42% |
| 4 | Financials | 10.33% |
| 5 | Communication Services | 9.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Enovis
ENOV
$1.84B
| – | – |
-29,389
| Closed | -$2.22M |
|
1627
Energizer
ENR
$1.97B
| – | – |
-68,618
| Closed | -$3.26M |
|
1628
FIVE9
FIVN
$2.07B
| – | – |
-58,688
| Closed | -$9.18M |
|
1629
Frontline
FRO
$4.9B
| – | – |
-109,665
| Closed | -$802K |
|
1630
GoodRx Holdings
GDRX
$1.45B
| – | – |
-82,714
| Closed | -$3.23M |
|
1631
GSK
GSK
$80.6B
| – | – |
-6,938
| Closed | -$310K |
|
1632
Hess Midstream
HESM
$5.4B
| – | – |
-95,238
| Closed | -$2.14M |
|
1633
Hovnanian Enterprises
HOV
$917M
| – | – |
-2,330
| Closed | -$246K |
|
|
IGMS
1634
DELISTED
IGM Biosciences
IGMS
| – | – |
-268,933
| Closed | -$20.6M |
|
1635
Independent Bank
INDB
$3.65B
| – | – |
-157,625
| Closed | -$13.3M |
|
1636
Ionis Pharmaceuticals
IONS
$9.52B
| – | – |
-76,644
| Closed | -$3.45M |
|
1637
Iovance Biotherapeutics
IOVA
$829M
| – | – |
-78,211
| Closed | -$2.48M |
|
|
JWN
1638
DELISTED
Nordstrom
JWN
| – | – |
-57,181
| Closed | -$2.17M |
|
1639
Coca-Cola Femsa
KOF
$17.6B
| – | – |
-527,195
| Closed | -$24.3M |
|
1640
Kymera Therapeutics
KYMR
$3.07B
| – | – |
-397,708
| Closed | -$15.5M |
|
1641
Pulmonx
LUNG
$72.5M
| – | – |
-152,082
| Closed | -$6.96M |
|
1642
MGP Ingredients
MGPI
$618M
| – | – |
-3,615
| Closed | -$214K |
|
1643
Middleby
MIDD
$7.32B
| – | – |
-7,730
| Closed | -$1.28M |
|
1644
Miller Industries
MLR
$482M
| – | – |
-5,014
| Closed | -$232K |
|
1645
MP Materials
MP
$11.5B
| – | – |
-96,587
| Closed | -$3.47M |
|
1646
Neogen
NEOG
$1.26B
| – | – |
-61,488
| Closed | -$2.73M |
|
1647
Nektar Therapeutics
NKTR
$671M
| – | – |
-3,922
| Closed | -$1.18M |
|
1648
Nutanix
NTNX
$18.8B
| – | – |
-141,061
| Closed | -$3.75M |
|
1649
Nu Skin
NUS
$605M
| – | – |
-17,500
| Closed | -$926K |
|
1650
OGE Energy
OGE
$8.92B
| – | – |
-14,262
| Closed | -$462K |
|